Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q2 FY22 results · Jul–Sep 2021
Natco Pharma reported revenue from operations of ₹377.20 crore (down 53.0% from Q2 FY21) and net profit of ₹65.10 crore (down 68.1% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 377.20 | 802.20 | −53.0% | 410.30 | −8.1% |
| Other income | 38.00 | 25.70 | +47.9% | 17.00 | +123.5% |
| Total income | 415.20 | 827.90 | −49.8% | 427.30 | −2.8% |
| Profit before tax | 69.80 | 270.70 | −74.2% | 91.00 | −23.3% |
| Net profit for the period | 65.10 | 203.90 | −68.1% | 75.00 | −13.2% |
| EPS, basic (₹) | 3.57 | 11.12 | −67.9% | 4.11 | −13.1% |
| Net margin (%) | 17.3 | 25.4 | 18.3 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 330.40 | 478.90 | −31.0% | 393.80 | −16.1% |
| Other income | 40.30 | 27.20 | +48.2% | 12.30 | +227.6% |
| Total income | 370.70 | 506.10 | −26.8% | 406.10 | −8.7% |
| Profit before tax | 52.30 | 86.50 | −39.5% | 91.00 | −42.5% |
| Net profit for the period | 53.60 | 70.90 | −24.4% | 75.20 | −28.7% |
| EPS, basic (₹) | 2.94 | 3.89 | −24.4% | 4.12 | −28.6% |
| Net margin (%) | 16.2 | 14.8 | 19.1 |
Consolidated
- Filed with BSE
- 11 Nov 2021, 17:17 IST
- Board meeting
- 11 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Nov 2021, 17:17 IST
- Board meeting
- 11 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE